Quarterly ResultMay 12, 2026, 07:02 AM
C4 Therapeutics advances cemsidomide, expands Roche partnership
AI Summary
C4 Therapeutics reported Q1 2026 financial results and significant business advancements. The company progressed plans for cemsidomide as a potential foundational treatment for multiple myeloma, with ongoing enrollment in Phase 2 MOMENTUM and Phase 1b trials, and a new Phase 1b trial expected in H1 2027. C4T also expanded its partnership with Roche through a new collaboration focused on degrader antibody conjugates, receiving a $20 million upfront payment. Financially, the company reported $6.2 million in revenue and a net loss of $25.1 million, with a strong cash position of $268.3 million providing a runway to the end of 2028.
Key Highlights
- Expanded long-term partnership with Roche for degrader-antibody conjugates; received $20M upfront payment.
- Cemsidomide Phase 2 MOMENTUM trial enrollment ongoing; Phase 1b trial with elranatamab initiated.
- Additional Phase 1b trial for cemsidomide with approved MM therapies expected to initiate in H1 2027.
- Decided not to advance CFT8919 into next clinical phase outside Greater China.
- Q1 2026 total revenue was $6.2 million, down from $7.2 million in Q1 2025.
- Q1 2026 net loss was $25.1 million, improved from $26.3 million in Q1 2025.
- Cash, cash equivalents and marketable securities totaled $268.3 million as of March 31, 2026.
- Company expects current cash to fund operations to the end of 2028.